Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals
- PMID: 25295005
- PMCID: PMC4172065
- DOI: 10.3389/fnagi.2014.00254
Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals
Abstract
Current treatment options for patients with Alzheimer's disease (AD) are limited at providing symptomatic relief, with no effects on the underlying pathophysiology. Recently, advances in the understanding of the AD pathogenesis highlighted the role of ABeta (Aβ) oligomers particularly interfering with mechanisms of cortical plasticity such as long-term potentiation (LTP) and long-term depression (LTD). These findings led to the development of potential anti-amyloid therapies, and among them homotaurine, a glycosaminoglycan mimetic designed to interfere with the actions of Aβ early in the cascade of amyloidogenic events, and by its γ-aminobutyric acid type (GABA) A receptor affinity. Recently, we showed that AD patients have impaired LTP-like cortical plasticity, as measured by standard theta burst stimulation protocols applied over the primary motor cortex (M1). Furthermore, AD patients have a weakened short latency afferent inhibition (SLAI), a neurophysiological measure of central cholinergic transmission, which changes reflect the cholinergic dysfunction occurring in the pathology. Here, we aimed at investigating whether homotaurine administration could modulate in vivo measured mechanisms of synaptic plasticity, namely LTP and LTD, and also SLAI in a group of mild cognitive impaired patients. We observed that homotaurine administration did not induce relevant changes of both LTP and LTD recordings, while induced changes of SLAI in our group of patients. We suggest that homotaurine effects are dependent on changes of cortical GABA transmission suggesting a potential role for this compound in ameliorating the cholinergic transmission by modulating the inhibitory cortical activity.
Keywords: GABA; MCI; SLAI; cortical interneurons; homotaurine.
Figures
Similar articles
-
Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients.Neuropsychopharmacology. 2014 Oct;39(11):2654-61. doi: 10.1038/npp.2014.119. Epub 2014 May 26. Neuropsychopharmacology. 2014. PMID: 24859851 Free PMC article. Clinical Trial.
-
Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer's disease patients.Front Aging Neurosci. 2013 Feb 19;5:2. doi: 10.3389/fnagi.2013.00002. eCollection 2013. Front Aging Neurosci. 2013. PMID: 23423358 Free PMC article.
-
Reversal of LTP-Like Cortical Plasticity in Alzheimer's Disease Patients with Tau-Related Faster Clinical Progression.J Alzheimers Dis. 2016;50(2):605-16. doi: 10.3233/JAD-150813. J Alzheimers Dis. 2016. PMID: 26757193
-
Transcranial magnetic stimulation as a tool to induce and explore plasticity in humans.Handb Clin Neurol. 2022;184:73-89. doi: 10.1016/B978-0-12-819410-2.00005-9. Handb Clin Neurol. 2022. PMID: 35034759 Review.
-
Do studies on cortical plasticity provide a rationale for using non-invasive brain stimulation as a treatment for Parkinson's disease patients?Front Neurol. 2013 Nov 6;4:180. doi: 10.3389/fneur.2013.00180. Front Neurol. 2013. PMID: 24223573 Free PMC article. Review.
Cited by
-
TMS-derived short afferent inhibition discriminates cognitive status in older adults without dementia.Aging Brain. 2024 Jul 19;6:100123. doi: 10.1016/j.nbas.2024.100123. eCollection 2024. Aging Brain. 2024. PMID: 39132326 Free PMC article.
-
Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease.Sci Rep. 2014 Dec 12;4:7467. doi: 10.1038/srep07467. Sci Rep. 2014. PMID: 25502280 Free PMC article.
-
Randomized, sham-controlled, clinical trial of repetitive transcranial magnetic stimulation for patients with Alzheimer's dementia in Japan.Front Aging Neurosci. 2022 Oct 13;14:993306. doi: 10.3389/fnagi.2022.993306. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36313021 Free PMC article.
-
Homotaurine in Parkinson's disease.Neurol Sci. 2015 Sep;36(9):1581-7. doi: 10.1007/s10072-015-2201-6. Epub 2015 Apr 19. Neurol Sci. 2015. PMID: 25894843 Clinical Trial.
-
New Drugs from Marine Organisms in Alzheimer's Disease.Mar Drugs. 2015 Dec 25;14(1):5. doi: 10.3390/md14010005. Mar Drugs. 2015. PMID: 26712769 Free PMC article. Review.
References
-
- Aisen P. S., Gauthier S., Ferris S. H., Saumier D., Haine D., Garceau D., et al. (2011). Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase study). Arch. Med. Sci. 7, 102–11110.5114/aoms.2011.20612 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources